The opportunity to redefine the treatment of major diseases is what drives everyone at Vertex. Our development portfolio represents the fruit of these efforts. Spend some time here and look around. Click on the pipeline chart to get information on our development programs and links to selected published articles. Go further and see how, just maybe, disease challenges may be overcome with innovation.

VX-759
(HCV Infection)

VX-759 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that completed Phase 1b clinical development. Vertex gained VX-759 as part of its acquisition of ViroChem Pharma Inc. in March 2009.